Resmetirom

瑞司美替罗

Report date: 2026/03/13 20:02:36
NMEFirst In Class

Base Information

Drug NameResmetirom
Drug Alias NameTHR beta agonists (VIA Pharmaceuticals)RezdiffraMGL-3196VIA-3196
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionThyroid hormone receptor beta-1 agonists
TargetsThyroid hormone receptor beta
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaDrug-Related Side Effects and Adverse ReactionsRenal Insufficiency +[6] 
Global Approved IndicationsLiver CirrhosisMetabolic Dysfunction-Associated Steatotic Liver Disease
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/03/14
Country/TerritoryBelgiumCanadaUnited States +[20] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMycovia Pharmaceuticals IncMadrigal Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsRenal InsufficiencyLiver CirrhosisHepatic Insufficiency +[4] 
Inactive IndicationsHeterozygous familial hypercholesterolemiaDrug-Related Side Effects and Adverse Reactions

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG